Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). No substantive Regulation FD disclosure included in the provided text.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- No substantive Regulation FD disclosure included in the provided text
- Investor impact cannot be assessed from this excerpt alone
Item 8.01 · Other Events
- Phase 2b CEDAR study failed efficacy objective, with placebo AN-count reduction of 57.1% versus 45.5% and 40.3% for brensocatib
- INSMED will discontinue brensocatib development in hidradenitis suppurativa, eliminating this program’s future commercial opportunity
- Study enrolled 214 patients across 72 global sites, randomized among 10 mg, 40 mg, and placebo arms
- Safety broadly comparable, with serious TEAEs of 4.1% at 10 mg, 1.4% at 40 mg, and 1.4% with placebo
Item EX-99.1 · Exhibit EX-99.1
- Phase 2b CEDAR failed primary and secondary efficacy endpoints at both 10 mg and 40 mg doses
- Insmed discontinuing brensocatib’s hidradenitis suppurativa development program, removing a potential pipeline opportunity
- Placebo showed 57.1% reduction in abscess and inflammatory nodule count versus 45.5% at 10 mg and 40.3% at 40 mg
- Safety remained consistent, with serious adverse events at 4.1% for 10 mg, 1.4% for 40 mg, and 1.4% for placebo
- Study enrolled 214 patients across 72 global sites, limiting further near-term HS development catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.